Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biopharma Co., Ltd.

Medshine Discovery Inc.

Other

Chinese Academy of Sciences

Shanghai Institute of Pharmaceutical Industry

Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd.

Shouyao Holdings (beijing) Co., Ltd.

Nanjing Gear Pharma & Tech Co., Ltd.

Advenchen Laboratories Nanjing Ltd

Hongjiang Xu

Xiquan Zhang

Ling Yang

Xiaojin Wang

Fei Liu

Shanchun Wang

Wei Shi

Wei Song

Yinsheng Zhang

Yong Peng

Yongxin Han

Hong Luo

Xin Tian

Yuandong Hu

Hongmei Gu

Dandan Lu

Tianxiao Zhao

Xingfeng Ge

Jie Wang

Xushi Liu

Ying Zhang

Wangwei Ao

Yuan Li

Song Tang

Jie Wu

Kai Cao

Weiwei Feng

Xueqin Ma

Li Zhang

Hui Wang

Shuo Chen

Hangzhou Shen

Jie Ni

Huan Zhang

Peng Lu

Shuhui Chen

Hui Zhang

Bo Liu

Charles Z Ding

Na Zhao

Yan Zhu

Rui Zhao

Xijie Liu

Yinghui Sun

Ping Dong

Yizhong Zhu

Shulong Wang

Yanlong Liu

Zhilin Chen

Ticong Huang

Xianxing Shang

Huifeng Xiao

Wei Wei

Jingli Wu

Xujing Tang

Jianqing Zhang

Jinan Wang

Bin Wang

Jian Li

Yu Wang

Wei Huang

Wei Wu

Yu Huang

Kai Zhou

Li Zhu

Fei Sun

Guoping Hu

Kevin X Chen

Xiaomin Zhang

Zhedong Yuan

Xunqiang Wang

Yanqing Yang

Jian Zhou

Wenhui Hu

Xueyan Zhu

Fansheng Kong

Xiaolong Wang

Boyu Hu

Xiaobing Yan

Lifang Wu

Liguang Dai

Xiaowei Duan

Yanxin Yu

Linghui Wu

Huting Wang

Hao Yu

Hubo Wang

Meng Guo

Chang Lu

Xiangjian Wang

Lei Chen

Jijun Li

Xiaolong Jiang

Hongjian Jiang

Zhongnan Xu

Hongying Zhang

Qin Yan

Hui Fu

Jinhua Du

Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Trifluoromethyl-substituted sulfonamide as BCL-2-selective inhibitor

A drug combination containing a TLR7 agonist. Specifically, a drug combination jointly using the compound of formula I acting as a TLR7 agonist and entecavir for the treatment of hepatitis B virus infection and a use thereof, the drug combination having a good anti-hepatitis B virus infection effect.

Drug combination containing TLR7 agonist

Disclosed is a methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor; specifically disclosed are a compound of formula I, a stereoisomer or pharmaceutically acceptable salt of same, a preparation method therefor, and a pharmaceutical composition comprising the compound. Also disclosed are uses of the compound and of the pharmaceutical composition comprising the compound in treating anti-apoptotic protein BCL-2-related diseases such as cancer.

Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective BCL-2 inhibitor

Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof

Disclosed are a compound of formula I as a toll-like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating colorectal cancer, a pharmaceutical combination for treating colorectal cancer comprising the TLR7 agonist and a tyrosine kinase inhibitor, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating colorectal cancer.

TLR7 agonist for treating colorectal cancer and pharmaceutical combination thereof

The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine kinase inhibitor for treating lung cancer, and the use of the compound of formula I or the pharmaceutically acceptable salt thereof and the pharmaceutical combination for treating lung cancer.

TLR7 agonist and pharmaceutical combination thereof for treating lung cancer

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

The present invention relates to a iminosulfanone compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof

The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

Furo[3,4-b]pyrrole-containing BTK inhibitor

The invention discloses a crystal of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine compound, a mesylate salt and crystal thereof, a preparation method thereof, a composition containing thereof, and a use thereof for inhibiting activity of mutant IDH2 and treating cancer.

Crystalline forms of 4-(tert-butoxyamino)-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1,3,5-triazin-2-amine

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection. 

Disclosed are a class of anti-HBV tetrahydroisoxazolo[4,3-c]pyridine compounds and pharmaceutically acceptable salts thereof or isomers thereof, the compounds being represented by the formula (I). 

Anti-HBVtetrahydroisoxazolo[4,3-c]pyridine compounds

The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.

Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases

A bicyclic compound acting as a ROR&#x3b3; inhibitor. Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof, the compound having a structure as represented by formula (I-A) or formula (I-B). The provided compound of formula (I-A) or formula (I-B) or pharmaceutically acceptable salt thereof has good ROR&#x3b3; inhibitory activities, being expected to be used for treating diseases mediated by ROR&#x3b3; receptors in a mammal. 

Bicylic compound acting as an inhibitor

Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a ROR&#x3b3; inhibitor, said compound has good ROR&#x3b3; inhibitory activity and is expected to be used for treating diseases mediated by a ROR&#x3b3; receptor in mammals. 

Sulfonyl substituted bicyclic compound which acts as ROR inhibitor

Growing community of inventors

Lianyungang, China

Hongjiang Xu